Comments
Indian vaccine manufacturer Bharat Biotech has not been granted permission to carry out simultaneous Phase 1 and Phase 2 trials for its nasal coronavirus vaccine candidate, CNBC TV18 reported.
The decision has been taken by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation during a meeting held on January 19.
Watch this: Watch | SII, Bharat Biotech issue Covid-19 vaccine factsheet
The company sought approval for the trials of the vaccine that is being developed in collaboration with the Washington University School of Medicine and Ocugen — a vaccine maker based in the US.
The SEC asked Bharat Biotech to first carry out Phase 1 and submit the immunogenicity data before proceeding to the next phase of trial.
Bharat Biotech has claimed that the non-invasive, single-dose vaccine will be easier to administer and will be an eco-friendly vaccine that is efficacious in the long run.
Also read: Bharat Biotech to approach WHO for Covaxin pre-qualification
Krishna Ella, Chairman, Bharat Biotech, has said, as per the MoneyControl report: “An intranasal vaccine will not only be simple to administer but will also reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive.”
He added: “One drop of Bharat Biotech’s intranasal Covid-19 vaccine in each of the nostrils would be sufficient.”
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.